RELL2: A Non-Coding RNA Molecule with Potential as A Drug Target for Cancer and Other Diseases

Target Name: RELL2

NCBI ID: G285613

RELL2

RELL2: A Non-Coding RNA Molecule with Potential as A Drug Target for Cancer and Other Diseases

RELL2 (RELT-like 2), also known as RCAN-RELT, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. RELL2 is a small non-coding RNA molecule that plays a critical role in regulating gene expression and has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion.

Recent studies have identified RELL2 as a potential drug target for various diseases, including cancer. Studies have shown that inhibiting RELL2 can lead to the inhibition of cell proliferation and the regression of cancer tumors. Additionally, RELL2 has also been shown to be involved in the regulation of cellular processes that are associated with cancer, such as the regulation of apoptosis, angiogenesis, and inflammation.

Diseases and Cancer

RELL2 has been shown to be involved in the development and progression of various diseases, including cancer. Studies have shown that RELL2 is involved in the regulation of cell proliferation and has been shown to promote the growth and survival of cancer cells. Additionally, RELL2 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.

Studies have shown that inhibiting RELL2 can lead to the inhibition of cell proliferation and the regression of cancer tumors. This suggests that RELL2 may be an effective drug target for cancer treatment. Additionally, RELL2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. Angiogenesis is a critical process for the development and maintenance of tissues and organs, and is often involved in the development of cancer.

In addition to its role in cancer, RELL2 has also been shown to be involved in the regulation of inflammation. Inflammation is a critical process for maintaining tissue health and immune function, but can also contribute to the development and progression of diseases, including cancer.

Potential Therapies

Given its involvement in the regulation of cell proliferation, apoptosis, angiogenesis, and inflammation, RELL2 has potential as a drug target for various diseases, including cancer. Studies have shown that inhibiting RELL2 can lead to the inhibition of cell proliferation and the regression of cancer tumors. Additionally, RELL2 has been shown to have anti-inflammatory effects, which may make it an effective therapy for diseases that are characterized by inflammation, such as cancer.

In addition to its anti-inflammatory effects, RELL2 has also been shown to have anti-cancer effects. Studies have shown that inhibiting RELL2 can lead to the inhibition of cancer cell proliferation and the regression of cancer tumors. This suggests that RELL2 may be an effective drug target for cancer treatment.

Conclusion

In conclusion, RELL2 is a non-coding RNA molecule that has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. Additionally, RELL2 has been shown to be involved in the regulation of apoptosis, angiogenesis, and inflammation, as well as the development and progression of various diseases, including cancer. Given its potential as a drug target, RELL2 is an attractive target for the development of new therapies for cancer and other diseases.

Protein Name: RELT Like 2

Functions: Induces activation of MAPK14/p38 cascade, when overexpressed (PubMed:28688764). Induces apoptosis, when overexpressed (PubMed:19969290)

The "RELL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RELL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets